ERBB2 and breast carcinoma: Although lapatinib provides a new treatment option for the management of HER2 positive breast cancer patients, and the combination with capecitabine represents an active and consolidated treatment choice in trastuzumab-resistant disease, clinicians and patients still face a number of clinical challenges, including minimizing toxicity.